Helixgate

Helixgate

Uncategorized

Windward Bio gets $165M to take China-derived drug into Phase 3 asthma trial

Published

on

A Swiss biotech with two experimental medicines from China, plus an in-house discovery team, has brought in $165 million to advance into late-stage testing.

The startup, Windward Bio, has raised a …

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

FDA search for new CBER head focused on small group of final candidates

Published

on

The FDA has narrowed its search for a new leader of its Center for Biologics Evaluation and Research to three to four final candidates, according to a person familiar with the matter.

The agency hopes …

Continue Reading

Uncategorized

Celcuity strengthens case for ASCO-spotlighted breast cancer drug

The new data could support a broader approval submission for a therapy that is already under review and set to be showcased at the year’s biggest meeting for cancer research.

Read More

Published

on

The new data could support a broader approval submission for a therapy that is already under review and set to be showcased at the year’s biggest meeting for cancer research.

Read More

Continue Reading

Uncategorized

Passage cuts 75% of workforce after FDA trial design request

Published

on

Passage Bio, which has been working toward a registrational trial for a drug candidate whose indications include frontotemporal dementia, is exploring strategic alternatives in addition to cutting staff.

Continue Reading
Advertisement

Trending